Barclays PLC — Capital/Financing Update 2012

Apr 11, 2012

Final Terms

BARCLAYS BANK PLC

(Incorporated with limited liability in England and Wales)

BARCLAYS CAPITAL (CAYMAN) LIMITED

(Incorporated with limited liability in the Cayman Islands)

GLOBAL STRUCTURED SECURITIES PROGRAMME

for the issue of Securities

BARCLAYS BANK PLC

EUR 5,000,000 Equity Linked Notes due April 2016 (the "Notes")

Series NX00067187

under the Global Structured Securities Programme

Issue Price: 100 per cent. of par

This document constitutes the final terms of the Notes (the "Final Terms") described herein for the purposes of Article 5.4 of the Directive 2003/71/EC (the "Prospectus Directive") and is prepared in connection with the Global Structured Securities Programme established by Barclays Bank PLC (the "Bank") and Barclays Capital (Cayman) Limited ("BCCL") and is supplemental to and should be read in conjunction with the Base Prospectus dated 5 August 2011, as supplemented and amended from time to time, which constitutes a base prospectus (the "Base Prospectus") for the purpose of the Prospectus Directive. Full information on the Issuer and the offer of the Securities is only available on the basis of the combination of these Final Terms and the Base Prospectus. The Base Prospectus is available for viewing during normal business hours at the registered office of the Issuer and the specified office of the Issue and Paying Agent for the time being in London and copies may be obtained from such office. Words and expressions defined in the Base Prospectus and not defined in this document shall bear the same meanings when used herein.

The Issuer accepts responsibility for the information contained in these Final Terms. To the best of its knowledge and belief (having taken all reasonable care to ensure that such is the case) the information contained in these Final Terms is in accordance with the facts and does not contain anything likely to affect the import of such information.

Investors should refer to the sections headed "Risk Factors" in the Base Prospectus for a discussion of certain matters that should be considered when making a decision to invest in the Securities.

Barclays Capital

Final Terms dated 11 April 2012

The distribution of this document and the offer of the Securities in certain jurisdictions may be restricted by law. Persons into whose possession these Final Terms come are required by the Bank to inform themselves about and to observe any such restrictions. Details of selling restrictions for various jurisdictions are set out in "Purchase and Sale" in the Base Prospectus. In particular, the Securities have not been, and will not be, registered under the US Securities Act of 1933, as amended. Trading in the Securities has not been approved by the US Commodity Futures Trading Commission under the US Commodity Exchange Act of 1936, as amended. Subject to certain exceptions, the Securities may not at any time be offered, sold or delivered in the United States or to US persons, nor may any US persons at any time trade or maintain a position in such Securities.

Part A Terms and Conditions of the Securities

The Securities shall have the following terms and conditions, which shall complete, modify and/or amend the Base Conditions and/or any applicable Relevant Annex(es) set out in the Base Prospectus dated 5 August 2011.

Parties
Issuer:	Barclays Bank PLC
Guarantor:	N/A
Manager:	Barclays Bank PLC
Determination Agent:	Barclays Bank PLC
Issue and Paying Agent:	The Bank of New York Mellon
Stabilising Manager:	N/A
Registrar:	N/A
Italian Securities Agent:	N/A
CREST Agent:	N/A
Paying Agents:	N/A
Transfer Agent:	N/A
Exchange Agent:	N/A
Additional Agents:	N/A

THE SECURITIES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). SUBJECT TO CERTAIN EXCEPTIONS, THE SECURITIES MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, US PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT ("REGULATION S"). THESE FINAL TERMS HAVE BEEN PREPARED BY THE ISSUER FOR USE IN CONNECTION WITH THE OFFER AND SALE OF THE SECURITIES OUTSIDE THE UNITED STATES TO NON-US PERSONS IN RELIANCE ON REGULATION S AND FOR LISTING OF THE SECURITIES ON THE RELEVANT STOCK EXCHANGE, IF ANY, AS STATED HEREIN. FOR A DESCRIPTION OF THESE AND CERTAIN FURTHER RESTRICTIONS ON OFFERS AND SALES OF THE SECURITIES AND DISTRIBUTION OF THESE FINAL TERMS, THE BASE PROSPECTUS AND THE SUPPLEMENTAL PROSPECTUSES SEE "PURCHASE AND SALE" IN THE BASE PROSPECTUS.

Provisions relating to the Securities

1	(i)	Series:	NX00067187
	(ii)	Tranche:	1
2	Currency:		Euro ("EUR")
3	Notes:
	(i)	Aggregate Nominal Amount as at the Issue Date:	EUR 5,000,000
	(ii)	Specified Denomination:	EUR 1,000
	(iii)	Minimum Tradable Amount:	EUR 10,000 and EUR 1,000 thereafter
	(iv)	Calculation Amount as at the	Specified Denomination
		Issue Date:	For the purposes hereof, all references in the Conditions to "Calculation Amount per Security" shall be construed as references to "Calculation Amount" as defined in these Final Terms.
4	Certificates:		N/A
5	Form:
	(i)	Global/Definitive/Uncertificated	Global Bearer Securities:
		and dematerialised:	Permanent Global Security
	(ii)	NGN Form:	Applicable
	(iii)	Held under the NSS:	N/A
	(iv)	CGN Form:	N/A
	(v)	CDIs:	N/A
6	Trade Date:		13 January 2012
7	Issue Date:		11 April 2012
8		Redemption Date:	11 April 2016
9	Issue Price:		100 per cent. of the Aggregate Nominal Amount

Equity Linked Annex

apply to the Securities:

Provisions relating to interest (if any) payable on the Securities

12	Interest:	N/A
13	Interest Amount:	N/A
14	Interest Rate:	N/A
15	Screen Rate Determination:	N/A

11 The following Relevant Annex shall

16	ISDA Determination:	N/A
17	Margin:	N/A
18	Minimum/Maximum Interest Rate:	N/A
19	Interest Commencement Date:	N/A
20	Interest Determination Date:	N/A
21	Interest Calculation Periods:	N/A
	long Interest Calculation Periods:
22	Interest Payment Dates:	N/A
23	Day Count Fraction:	N/A
24	Fall back provisions, rounding provisions, denominator and any other terms relating to the method of calculating interest, if different from those set out in the Base Conditions:	N/A
	Provisions relating to Redemption

25	Settlement Method:	For the purposes of Condition 5.1 of the Base Conditions:
		Cash Settlement
26	Settlement Currency:	EUR
27	Settlement Number:	As defined in Condition 24 of the Base Conditions
28	Terms relating to Cash Settled Securities:

(i) Final Cash Settlement Amount: An amount in the Settlement Currency, payable on the Redemption Date in respect of each Calculation Amount, calculated as follows:

Calculation Amount x(100% + max
$$
\left(0\%;\sum_{n=1}^{4} \text{Return}_n\right)
$$

Where:

"k" represents an integer from 1 to 5.

"MinPerformance(k)(n)" means in respect of each Observation Date(n), the five lowest Shareⁱ Perf(n) as determined by the Determination Agent on such Observation Date(n).

"n" represents an Observation Date from 1 to 4.

"Observation Date(n)" means each date set out in Schedule 2.

"Returnn" is calculated as follows:

$$
\left(\frac{1}{15}x(10x7.85\% + \sum_{k=1}^{5} MinPerformance_{(k)(n)})\right)
$$

"Shareⁱ Perf(n)" is calculated as follows: Start i Start i n i Share Share Share

" n Shareⁱ " means in respect of each Share, the Share Price of such Share on any Observation Date(n).

" Start Shareⁱ " means in respect of each Share, the Share Price of such Share on the Strike Date.

"Share Price" means, in respect of each Share, the price of such Share at the Valuation Time on any Scheduled Trading Day.

"Strike Date" means 30 March 2012.

• (iii) Early Cash Redemption Date: As defined in Condition 24 of the Base Conditions
• 29 Terms relating to Physically Delivered Securities:
• 30 Nominal Call Event: N/A
• 31 Call Option: N/A
• 32 Put Option: N/A
• 33 Specified Early Redemption Event: N/A
• 34 Maximum and Minimum Redemption Requirements:
• 35 Additional Disruption Events in addition to those specified in Condition 24 of the Base Conditions and any applicable Relevant Annex:

36 Share Linked Securities: Applicable

• (i) Shares (each a "Reference Asset"):

(iv) Exchange Rate: N/A

(v) Weighting for each Reference Asset comprising the Basket of

(ii) Early Cash Settlement Amount: As defined in Condition 24 of the Base Conditions

N/A

N/A

N/A

A basket of 15 shares (each a "Share" and, collectively, the "Basket"), as set out in Schedule 1 (ii) Exchange: In respect of each Share, as set out in Schedule 1

• (iii) Related Exchanges: In respect of each Share, All Exchanges

Reference Assets:

	(vi)	Initial Price of each Reference Asset:	In respect of each Share, the Share Price on the Strike Date
	(vii)	Number of Shares:	N/A
	(viii)	Substitution of Shares:	Substitution of Shares - Standard is applicable
	(ix)	Valuation Date:	Each Observation Date(n)
	(x)	Valuation Time:	As defined in the Equity Linked Annex
	(xi)	Averaging:	N/A
	(xii)	Additional Disruption Event in respect of Share Linked Securities:	N/A
	(xiii)	FX Disruption Event:	N/A
	(xiv)	Market Access Dividend and Rights Issue Provisions:	N/A
	(xv)	Dividend Exchange Rate:	N/A
	(xvi)	Other adjustments:	N/A
37		Index Linked Securities:	N/A
38		Inflation Linked Securities:	N/A
39	FX Linked Securities:		N/A
40		Credit Linked Securities:	N/A
41		Commodity Linked Securities:	N/A
42		(a) Barclays Capital Commodity Index Linked Securities (Section 2 of the Barclays Capital Index Annex):	N/A
		(b) Barclays Capital Equity Index Linked Securities (Section 3 of the Barclays Capital Index Annex):	N/A
		(c) Barclays Capital FX Index Linked Securities (Section 4 of the Barclays Capital Index Annex):	N/A
		(d) Barclays Capital Interest Rate Index Linked Securities (Section 5 of the Barclays Capital Index Annex):	N/A
		(e) Barclays Capital Emerging Market Index Linked Securities (Section 6 of the Barclays Capital Index Annex):	N/A
43		Bond Linked Securities:	N/A

7

44		Fund Linked Securities:	N/A
		Provisions relating to Settlement
45	Settlement in respect of VP Notes, APK Registered Securities, Dutch Securities, Swedish Registered Securities, VPS Registered Securities or Spanish Securities:		N/A
46	Additional provisions relating to Taxes and Settlement Expenses:		N/A
	Definitions
47	Business Day:		As defined in Condition 24 of the Base Conditions
48		Additional Business Centre(s):	N/A
		Selling restrictions and provisions relating to certification
49		Non-US Selling Restrictions:	As described in the Base Prospectus
50		Applicable TEFRA exemption:	Not Applicable
	General
51		Business Day Convention:	Modified Following
52		Relevant Clearing Systems:	Euroclear
			Clearstream
53		If syndicated, names of Managers:	N/A
54	(a)	Details relating to Partly Paid Securities:	N/A
	(a)	Details relating to Instalment Notes:	N/A
55		Relevant securities codes:	ISIN: XS0549893344
			Common Code: 054989334
56	Modifications to the Master Subscription Agreement and/or Agency Agreement:		N/A
57	Securities:	Additional Conditions and/or modification to the Conditions of the	For the purposes hereof, Condition 9.7 of the Base Conditions shall be modified so that if the due date for any payment in respect of any Security or Coupon is not a Payment Day, then payment will not be made until the next succeeding Payment Day in the relevant place unless it would thereby fall into the next calendar month, in which event such date shall be brought forward to the immediately

preceding Payment Date, and the holder thereof

shall not be entitled to any further payment in respect of any such delay.

Part B Other Information

1 Listing and Admission to Trading

(i)	Listing:	London
(ii)	Admission to trading:	Application is expected to be made by the Issuer (or on its behalf ) for the Securities to be admitted to trading on the London Stock Exchange's Regulated Market.
(iii)	Estimate of total expenses related to admission to trading:	N/A

2 Ratings

Ratings: The Securities have not been individually rated.

3 Notification

The Financial Services Authority of the United Kingdom has provided the Central Bank of Ireland with a certificate of approval attesting that the Base Prospectus has been drawn up in accordance with the Prospectus Directive.

4 Interests of Natural and Legal Persons involved in the Issue

Save as discussed in "Purchase and Sale", so far as the Issuer is aware, no person involved in the offer of the Securities has an interest material to the offer.

5 Reasons for the Offer, Estimated Net Proceeds and Total Expenses

(i)	Reasons for the offer:	General funding

• (ii) Estimated net proceeds: N/A
• (iii) Estimated total expenses: N/A

6 Fixed Rate Securities Only – Yield

N/A

7 Floating Rate Securities Only – Historic Interest Rates

N/A

8 Performance of Reference Asset(s) or Other Variable, Explanation of Effect on Value of Investment and Associated Risks and Other Information Concerning the Reference Asset(s) and/or Other Underlying

Past and further performance (including volatility) of each Share can be obtained on Bloomberg/Reuters.

Investors should note that historical performance should not be taken as an indication of future performance.

The Issuer does not intend to provide post-issuance information.

9 Performance of Rate of Exchange and Explanation of Effect on Value of Investment

N/A

10 Operational Information

	Any clearing system(s) other than Euroclear Bank S.A./N.V. and Clearstream Banking, société anonyme (together with their addresses) and the relevant identification number(s):	N/A
	Delivery:	Delivery free of payment
	Names and addresses of additional Paying Agents(s) (if any):	N/A
	Intended to be held in a manner which would allow Eurosystem eligibility:	Yes Note that the designation "yes" simply means that the Securities are intended upon issue to be deposited with one of the International Central Securities Depositaries ("ICSDs") as common safekeeper and does not necessarily mean that the Securities will be recognised as eligible collateral for Eurosystem monetary policy and intra-day credit operations by the Eurosystem, either upon issue or at any or all times during their life. Such recognition will depend upon the ECB being satisfied that Eurosystem eligibility criteria have been met.
11	Offer Information
	Offer Price:	Issue Price

The Issue Price includes a commission element to be shared with a third party which shall not exceed 5 per cent. of the Issue Price, further details of which are

	available upon request.
Conditions to which the offer is subject:	The Issuer reserves the right to withdraw the offer for Securities at any time on or prior to the end of the Offer Period (as defined below). Following withdrawal of the offer, if any application has been made by any potential investor, each such potential investor shall not be entitled to subscribe or otherwise acquire the Securities and any applications will be automatically cancelled and any purchase money will be refunded to the applicant by the Distributor in accordance with the Distributor's usual procedures.
Description of the application process:	An offer of the Securities may be made by the Manager or the Distributor other than pursuant to Article 3(2) of the Prospectus Directive in Ireland (the "Public Offer Jurisdiction") during the period from and including 20 January 2012 to and including 30 March 2012 (the "Offer Period"). Applications for the Securities can be made in the Public Offer Jurisdiction through the Distributor during the Offer Period. The Securities will be placed into the Public Offer Jurisdiction by the Distributor. Distribution will be in accordance with the Distributor's usual procedures, notified to investors by the Distributor.
Details of the minimum and/or maximum amount of application:	The minimum and maximum amount of application from the Distributor will be notified to investors by the Distributor.
Description of possibility to reduce subscriptions and manner for refunding excess amount paid by applicants:	Subscription orders may be reduced in case of oversubscription, excess amount of funds paid being reduced without delay with no entitlement for compensation.
Details of method and time limits for paying up and delivering the Securities:	Investors will be notified by the Distributor of their allocations of Securities and the settlement arrangements in respect thereof.
Manner in and date on which results of the offer are to be made public:	Not Applicable
Procedure for exercise of any right of pre emption, negotiability of subscription rights and treatment of subscription rights not exercised:	Not Applicable

Categories of prospective investors to which the Securities are offered and whether tranche(s) have been reserved for certain countries:

Process for notification to applicants of the amount allotted and indication whether dealing may begin before notification is made:

Amount of any expenses and taxes specifically charged to the subscriber or purchaser:

Name(s) and address(es), to the extent known to the Issuer, of the placers in the various countries where the offer takes place:

Offers may be made by the Manager or the Distributor in the Public Offer Jurisdiction to any person. Offers (if any) in other EEA countries will only be made by the Manager or the Distributor pursuant to an exemption from the obligation under the Prospectus Directive as implemented in such countries to publish a prospectus.

Each investor will be notified by the Distributor of its allocation of Securities at the time of such investor's application.

No dealings in the Securities may take place prior to the Issue Date.

Not Applicable

Quintas Wealth Management Limited (the "Distributor") Heron House Blackpool Park Blackpool Cork Ireland

Schedule 1

The Basket

i	Share	Exchange	Bloomberg / Reuters code
1	Johnson & Johnson	New York Stock Exchange	JNJ UN Equity
2	Novartis Ag Reg	Six Swiss Ex	NOVN VX Equity
3	Pfizer Inc	New York Stock Exchange	PFE UN Equity
4	Roche Holding AG Genusschein	Six Swiss Ex	ROG VX Equity
5	Glaxosmithkline PLC	London Stock Exchange	GSK LN Equity
6	Merck & Co .INC	New York Stock Exchange	MRK UN Equity
7	Sanofi	Euronext	SAN FP Equity
8	Abbott Laboratories	New York Stock Exchange	ABT UN Equity
9	Astrazeneca PLC	New York Stock Exchange	AZN LN Equity
10	Amgen INC	Nasdaq	AMGN UQ Equity
11	UnitedHealth Group PLC	New York Stock Exchange	UNH UN Equity
12	Bristol-Myers Squibb Co	New York Stock	BMY UN Equity

		Exchange
13	Teva	Nasdaq	TEVA UQ
	Pharmaceutica l- SP ADR		Equity
14	ELI LILLY & Co	New York	LLY UN
		Stock	Equity
		Exchange
15	Medtronic Inc	New York	MDT UN
		Stock	Equity
		Exchange

Schedule 2 Observation Dates

n	Observation Date
1	2 April 2013
2	31 March 2014
3	30 March 2015
4	30 March 2016